{"name":"Visterra, Inc.","slug":"visterra-inc","ticker":"","exchange":"","domain":"","description":"Visterra, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. The company has a pipeline of 10 drug candidates, with several in early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Low dose of VIS410","genericName":"Low dose of VIS410","slug":"low-dose-of-vis410","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Low dose of VIS410","genericName":"Low dose of VIS410","slug":"low-dose-of-vis410","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbkxRQXhQZmpLZWxReC02aWttT3d3QkFLSlZiSFhBLXA4cFZnMUVfMU1SLWxmZlY4NDBYYllORExMWUY4dHhLV2tGV3ZTaEEzY1FQZVRkZEVNaWpDYW9qNFlibFlKbTc2WWFqckljVm5YcTVsMTVfaHV6VktoNEw5SzhhQk5uLTdSWEdWdw?oc=5","date":"2025-11-26","type":"regulatory","source":"Pharmacy Times","summary":"FDA Approves Sibeprenlimab for Patients with IgAN - Pharmacy Times","headline":"FDA Approves Sibeprenlimab for Patients with IgAN","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQWnJNTDQ0QVotdzEzNnVxTWZ2ODkyaWZfeFE2eUhaNE9qMU1rRmNGNGc5Ry1DelFNRWVUcm85YVZSQUN3SE8yOEw5UTdXb0Q0b2t0dkpBdUpFRXlqRlBDcFZxV2ZSdVdRNGY2NTV5alRTSWxnOTIzZVBFYnZQQ01wcHlSNUZOMlBieExxSlNaa2FYdFlnSUNEMC0tRjJNSEJSMGE2c0hfazQyOWJ4UmFSNjJ5SElyMkZFTUIwRHNiQTB0YkhLb091Rw?oc=5","date":"2025-10-23","type":"pipeline","source":"Healio","summary":"Complete hair regrowth for some with alopecia after 3-year ritlecitinib treatment - Healio","headline":"Complete hair regrowth for some with alopecia after 3-year ritlecitinib treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-12","type":"trial","source":"Mynewsdesk","summary":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN) - Mynewsdesk","headline":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPNjN2UWozM0I4MGFkdzl5M1JaZ2VnVWpscklDVmdHd29mQjZ1VWxaSGNmWTdqNHR2WWZfUm5GdF9iUm5rVEt2UUJMTGo3ci1OcFZRdDZkcDA5YjNuYmx2MnRWYUFzRVEzdGVoMzBpRFZjRE9uVGlQVmZQTHNQQkRRQ3pKMTV6S25WSWtzbDFPUGRjc0gweGM4UVItSUp0ZVlUZ3VQR3BJSTY4QkVjNHIzc2FjWEZOX2pqMmNYNENNY0lQeVk0UHhucGhGeFR1LVFtME9aZk5ybmdZVG9adE10dmpScFBjNTBGVlhsd2JyaTdvV25UNVV5WTJpX19ROTZDUnhyMFdIZlRmWHlKLWJsVTJ4U0pzWjk4YmtENlRZRDRqMTVjRUJmLW56cFlOdmNlZWRV?oc=5","date":"2025-06-06","type":"trial","source":"BioSpace","summary":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN) - BioSpace","headline":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQTmZuS1lpOTF1cTZBOW0yRjBiWXJRWmZKb1pJbnVsZUlkak1Sc1JGLWlKSDJMbjFYWVl0SUFfeDMtZnlseE55RW83VVJMUk1nbm1SdTJCTHUwdTV3azhObTZGTXh0MUxCeU5XSnE0bVViVmxUTGhldDFwTXVudlBfQ2wtUE9yOVFlOXh5UkQ0THI?oc=5","date":"2024-10-22","type":"pipeline","source":"BioPharma Dive","summary":"Otsuka’s startup bet pays off with kidney disease drug results - BioPharma Dive","headline":"Otsuka’s startup bet pays off with kidney disease drug results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVphLXo1MW9TYU5Fd3VOVHJxQjB3YllnQkRvNmdYTktod2JTWkxSYU10VE9MZ01XWGR4d2xjaEZmSjNMdzV6bk4tZXZYYnM1Vk5zbHNuMUpQcHRjVVBxUDltaU4wVmI5WGhWZkcwSkdRNXhubUVtYjBkdzNHUko1V3lHTkI0blBUZlZVa1RhQjZ0ZWozc0pRbF9TalVVMnRs?oc=5","date":"2024-08-06","type":"deal","source":"BioWorld News","summary":"Otsuka to buy Boston chemoproteomics biotech for up to $1.1B - BioWorld News","headline":"Otsuka to buy Boston chemoproteomics biotech for up to $1.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxPT3pxQl9oQnl0LWJVdUxfcHVjS25YclRINy1yY3E4ZWVLRTJnMS1VVF9UNktZakkzQktJZlZvTzdTa1NYRDBlOUVuTGlVQWgzWDAxT2kyX0tXMVNoRW9SZmhtU3FZWTAtcFFPbmcxZHFVTFVRbEVpWU9aTF9KaWlkU3ZPTERoc1J4Qzlvb0YxWnk2Qk5pWHItVW55bWNJY2p1bHZ4cm9XNEk3Rkt1cDZFWGE2N05OTFgzeGF6T1NCeFg4NUFXN2pvTEFaWC1nZU1TSkN3UFRjY2FCZ2J6ZnJ4NmZQc1hKOEFpMU9yYURISHZtRXlJY3JoOU9jQURVQl9L?oc=5","date":"2024-02-16","type":"regulatory","source":"Business Wire","summary":"Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy - Business Wire","headline":"Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNSDAwbWxCRVl6anZSMVZ4ci10ZHBvclBoTDRvTHdlNmRSTERPY3ZkZjJvWnhOV3NuSUcwSG9rZTFPUWs0OWhTNU9jSHRXaFpvXzdZYmJSUjhLSDZvLVA2RTFsN2tXQ3RkUVNWRGtUNDQzQjBibG41UkVhNjNQTnVZQlgtNU5xc3E5LThVeGpmY1E1cU9kSDh0UkJKeWMtc0VOUEFBd0oyWXBnSnhwRmFSOUVn?oc=5","date":"2022-10-17","type":"pipeline","source":"citybiz","summary":"KalVista Pharmaceuticals Appoints Brian J.G. Pereira, M.D. as Board Chairman - citybiz","headline":"KalVista Pharmaceuticals Appoints Brian J.G. Pereira, M.D. as Board Chairman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQOGw5LUZHNm5zM294NEd2UEFGS0k3U3JEMHQxcVliVHZIdTUxclR5ZndSUWhUQUUzdG1tYS12ZE1wbWNEVVQtWGlFQUc2VFN5Sm9SaGlhenJPaDlDV0djT0h0dnZUR3lnZ2plMGxlcTBScWtDVXhUTkoyTDdxbElrNW9BUTc1M2VTS1k1Yk5sVFE4M0lVMmpydkRXOVNFZV9TYnFwLWstVEw?oc=5","date":"2018-07-11","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms - Genetic Engineering and Biotechnology News","headline":"Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPaVZFejBTOW52Q3l5NzBxS3JSWEVzYWM4THFJOUtvMHo4eWxpdndPdTZUVWUyN0c2dThwTUVtSHhYSlZJSEJFdjBYVXVIVzVzSlBPTXZyY3JCRFBQN0JFNnotZllDaTVoQWRrc0RYVnRVc1FBZzNsVjRuS1g2d2VfQlZyZndEbm5PUmFRRS12VmJydXlSRlhmMQ?oc=5","date":"2018-07-11","type":"deal","source":"Fierce Biotech","summary":"Otsuka to acquire antibody developer Visterra in $430M deal - Fierce Biotech","headline":"Otsuka to acquire antibody developer Visterra in $430M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQMXAzbDZqbElXcm1MSzc5djFLVHI4c2RrR3g1cUp1aXo5Z3RLYlBJNzJKTUd6S1ZmVWlBNWhUQTRxWERTU29WUUdNN0J6WHRZWENlVUhGdDlnUEZKMVF1ZWlDTG9MUE9CSGdzcHdYcFlSaDFXd0ZHMUEwcHJQdWhQMGZkdmNWQQ?oc=5","date":"2018-07-11","type":"deal","source":"BioSpace","summary":"Otsuka Pharmaceuticals Buying Visterra for $430 Million - BioSpace","headline":"Otsuka Pharmaceuticals Buying Visterra for $430 Million","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}